Skip to main content
. Author manuscript; available in PMC: 2010 Jun 1.
Published in final edited form as: Clin Cancer Res. 2009 Nov 24;15(23):7144–7152. doi: 10.1158/1078-0432.CCR-09-1483

Figure 3. 1339 inhibits STAT3, ERK1,2 and Akt signaling pathways.

Figure 3

MM1S cells were incubated with (A) IL-6 (5ng/ml, 10 and 30 minutes) or (B) with BMSC supernatant (30 minutes) in the absence or presence of 0.1 and 1 ug/ml of mAb 1339. Cells were harvested and whole cell lysates were subjected to immunoblotting using indicated Abs. 1339 inhibits both IL-6- and BMSC-induced activation of ERK 1, 2 and STAT3 pathway in MM cells, while a relatively lesser effect was observed with activation of AKT, as shown by densitometric quantitation of band intensity from WB (C). Data represent mean +/- SD, (N=3), and are presented as fold change increase compared to control cells.